3 New Strong Buy Ratings from Top-Rated Analysts: 01/06/2026

Looking for stock suggestions? Here’s what’s trending on our most popular screener:

• Amneal Pharmaceuticals (AMRX) is our Stock of the Week — for the second time in a month! 
• Teva Pharmaceutical Industries (TEVA) enjoys a positive pivot 
• Broadcom (AVGO) is back in the hot seat (in a good way)

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. Amneal Pharmaceuticals Inc (NASDAQ: AMRX)

Amneal Pharmaceuticals is our Stock of the Week — for the second time in a month. The company recently received FDA approval for Denosumab biosimilars and is expanding its specialty injectable drug portfolio with significant growth opportunities ahead. See below for more great reasons to watch this promising ticker. 

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $12.66 — get current quote

Max 1-year forecast: $15.00

Why we're watching:

• Analyst support: The stock has unanimous support with 3 Strong Buy ratings from all covering analysts, reflecting strong conviction in the stock. See the ratings
• For example, Piper Sandler's David Amsellem (a top 6% rated analyst) recently reiterated his Strong Buy rating with a $13 price target based on improving market conditions for generic pharmaceuticals.
• It’s also been featured as our Stock of the Week twice in the past month. For a more detailed breakdown of AMRX’s positive attributes, check out this video. 
• The company's portfolio expansion includes recent FDA approvals for Denosumab biosimilars referencing Prolia and XGEVA, as well as Epinephrine injection for U.S. hospitals, strengthening its competitive position.
• Industry ranking context: AMRX is currently the 3rd highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A.
• Zen Rating highlights: With its Strong Buy (A) rating, AMRX is in a class of stocks that have historically trounced the S&P with 32.52% average annual returns. 
• Component Grades: The stock shows comprehensive strength with Value at B grade, Growth at B reflecting strong earnings trajectory, Sentiment at A grade, and Momentum at B as the stock approaches 52-week highs. See all 7 Zen Component Grades here

2. Teva Pharmaceutical Industries (NYSE: TEVA)

This generic medicine manufacturer and distributor company recently received credit rating upgrades from S&P Global (to BB+) and a positive outlook revision from Moody's amid strong execution of its pivot to growth strategy.

Zen Rating: B (Buy) — see full analysis

Recent Price: $30.95 — get current quote

Max 1-year forecast: $40.00

Why we're watching:

• Analyst support: The stock has impressive backing with 6 Strong Buy ratings and 1 Buy rating out of 7 total analysts, delivering a Strong Buy consensus with an average price target of $34.00. See the ratings
• For example, Piper Sandler's David Amsellem (a top 6% rated analyst) recently maintained his Strong Buy rating with a $40 price target, representing +29.24% upside potential and the highest target among covering analysts.
• Notable institutional interest includes billionaire Stanley Druckenmiller holding a significant $1.2B position in Teva, signaling strong conviction from sophisticated investors in the company's long-term repair story.
• Industry ranking context: TEVA is currently the 17th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A.
• Zen Rating highlights: Buy (B) stocks average +19.88%/yr — TEVA shows strong earnings recovery with EPS forecast to grow +340.38% to $2.77 next year.
• Component Grades: The stock demonstrates balanced strength with Value at B grade, Growth at B reflecting the strong earnings trajectory, Momentum at B, and Safety at B. Financials grade at C as the company continues deleveraging efforts. See all 7 Zen Component Grades here

3. Broadcom Inc (NASDAQ: AVGO)

Broadcom is a major AI infrastructure beneficiary with record AI semiconductor revenues growing 74% year-over-year, driven by hyperscaler demand and new customers including Anthropic and xAI.

Zen Rating: B (Buy) — see full analysis

Recent Price: $347.62 — get current quote

Max 1-year forecast: $510.00

Why we're watching:

• Analyst support: The stock has overwhelming support from the analysts we track, with 16 Strong Buy ratings, 5 Buy ratings, and just 1 Hold out of 22 total analysts. See the ratings
• For example, Truist Securities' William Stein (a top 1% rated analyst) recently maintained his Strong Buy rating with a $510 price target, representing +46.71% upside potential and the highest target among all analysts.
• Speaking of top-tier analysts, UBS's Timothy Arcuri (a top 1% rated analyst) and Morgan Stanley's Joseph Moore (also top 1%) both recently maintained Strong Buy ratings. 
• Analysts are particularly confident in Broadcom's focus on AI accelerators and networking, with Q1 2026 AI semiconductor revenues projected to reach $8.2B, driven by major clients like Google and Meta Platforms.
• CEO commentary highlighted that Q4 record revenue of $18B grew 28% year-over-year, driven primarily by AI semiconductor revenue increasing 74% year-over-year, with expectations for AI semiconductor revenue to double year-over-year to $8.2B in Q1 2026. 
• Industry ranking context: AVGO is currently the 6th highest-rated stock out of 69 in the Semiconductor industry, which has an Industry Rating of C.
• Zen Rating highlights: Buy (B) stocks in our quant ratings system have historically averaged +19.88%/yr — but AVGO’s price targets suggest it could exceed this benchmark. 
• Component Grades: The stock shows particular strength in Financials, Sentiment, and Momentum, and from our proprietary AI rating (all above-average B grades).  See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.